Literature DB >> 3914645

Physiologic pharmacokinetic models and interanimal species scaling.

M Rowland.   

Abstract

Mesh：

Substances：

Year:  1985        PMID： 3914645     DOI： 10.1016/0163-7258(85)90016-6

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


× No keyword cloud information.
  12 in total

Review 1.  Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion.

Authors:  K Sandy Pang; Matthew R Durk
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  A comment on the application of drug tissue-plasma partition coefficients K(p) in eliminating organs to calculation of volume of distribution at steady state.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-12       Impact factor: 2.745

Review 4.  Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.

Authors:  S B Charnick; R Kawai; J R Nedelman; M Lemaire; W Niederberger; H Sato
Journal:  J Pharmacokinet Biopharm       Date:  1995-04

5.  Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up.

Authors:  Y Mitsuhashi; Y Sugiyama; S Ozawa; T Nitanai; K Sasahara; K Nakamura; M Tanaka; T Nishimura; M Inaba; T Kobayashi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

6.  Prediction of in vivo tissue distribution from in vitro data 1. Experiments with markers of aqueous spaces.

Authors:  P Ballard; D E Leahy; M Rowland
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

Review 7.  Challenges of using in vitro data for modeling P-glycoprotein efflux in the blood-brain barrier.

Authors:  Noora Sjöstedt; Hanna Kortejärvi; Heidi Kidron; Kati-Sisko Vellonen; Arto Urtti; Marjo Yliperttula
Journal:  Pharm Res       Date:  2014-01       Impact factor: 4.200

8.  Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models.

Authors:  Grace Zhixia Yan; Kim L R Brouwer; Gary M Pollack; Michael Zhuo Wang; Richard R Tidwell; James E Hall; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2011-02-14       Impact factor: 4.030

9.  Gentamicin volume of distribution as a power function of body weight.

Authors:  F Keller
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

10.  Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.

Authors:  S F Marshall; R Burghaus; V Cosson; S Y A Cheung; M Chenel; O DellaPasqua; N Frey; B Hamrén; L Harnisch; F Ivanow; T Kerbusch; J Lippert; P A Milligan; S Rohou; A Staab; J L Steimer; C Tornøe; S A G Visser
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.